Background. The transmission of drug-resistant human immunodeficiency virus type 1 (HIV-1) is a matter of major concern, because it could compromise the response to antiretroviral therapy.
mission of drug-resistant viruses is a matter of growing concern [5] [6] [7] [8] [9] [10] , because such transmission may compromise the success of antiretroviral therapy administered to newly infected individuals. Given that many drug resistance mutations compromise the replicative capacity of the virus [11] , hypothetically drug-resistant virus might show reduced transmission efficiency compared with wild-type strains [12] . Moreover, some specific drug resistance mutations that particularly affect viral fitness [13, 14] might impair transmission to a greater extent than others.
To test these hypotheses, we analyzed the rate of drug resistance mutations in patients with recent HIV-1 seroconversion (the seroconverter group) and compared it with the prevalence of drug resistance mutations in a group of individuals who were potential transmitters of HIV-1 (the potential transmitter group), all of whom were living in the same geographical area and were experiencing virologic failure while receiving antiretroviral therapy.
PATIENTS AND METHODS
Study population. The study was designed as a case-control study in which 2 different groups of patients were retrospectively selected. First, all individuals with recent HIV-1 seroconversion who engaged in high-risk sexual practices were identified in 2 large HIV outclinics located in Madrid, SpainHospital Carlos III, an HIV/AIDS reference institution, and Centro Sandoval, the largest clinic for sexually transmitted diseases in Madrid. The study covered 5.5 years, extending from January 1997 through June 2003. All individuals who had received a diagnosis of sexually acquired HIV-1 infection within the previous 12 months were selected for the study, including patients with primary HIV-1 infection and those with recent HIV-1 seroconversion. All subjects had laboratory evidence of acute primary HIV infection (i.e., had detectable plasma HIV RNA levels, together with a negative or indeterminate HIV antibody test result) or were seropositive for HIV-1 infection (i.e., had reactive ELISA and positive Western blot assay results), with a negative test result within the previous 12 months. The earliest plasma specimen available from each patient was tested in the present study.
The second group of patients-the potential transmitter group-consisted of individuals with chronic HIV-1 infection living in Madrid who had multiple plasma HIV RNA levels 11000 copies/mL despite having received triple-drug antiretroviral therapy for у6 months. These patients attended regular follow-up visits at Hospital Carlos III. These patients were paired by year and route of infection with the members of the seroconverter group. For each member of the seroconverter group, 6 paired members of the potential transmitter group were identified. Plasma specimens obtained from each of the study subjects were stored at Ϫ70ЊC until the time of the analysis. A case report form, including demographic data and clinical and laboratory parameters, was filled out with each individual's information.
Laboratory tests. The measurement of plasma HIV RNA levels was performed using a branched-DNA assay (Bayer), following manufacturer's instructions. The CD4 + T lymphocyte count was determined by flow cytometry (Coulter), using fluorescein-labelled antibodies.
Genetic sequence analyses of both HIV reverse-transcriptase (RT) and protease genes were carried out in all plasma specimens using an automatic sequencer (ABI Prism 3100; Celera Diagnostics). For the purpose of this study, only major or primary drug resistance mutations listed in the latest guidelines from the International AIDS Society-USA Panel were recorded [15] . The estimation of the transmission efficiency for drug resistance mutations was represented as a ratio derived from dividing the rate of drug resistance mutations in the seroconverter group by the corresponding rate found in the potential transmitter group. This ratio was applied to both drug families and specific drug-resistance genotypes. Therefore, a ratio of 1 meant a relative transmission efficiency of 100%, and a ratio of 0 meant no transmission.
Comparisons between categorical variables were assessed using Fisher's exact test. Differences between groups were considered to be significant when P values were !.05. All reported P values were 2-sided. Data analyses were performed using the SPSS software, version 10 (SPSS). 
RESULTS
A total of 89 members of the seroconverter group and 520 potential transmitters of drug-resistant virus were identified. They covered a 5.5-year period, extending from January 1997 through June 2003. Table 1 records the main features of the 2 study populations. Differences in CD4 + cell count and viral load values were observed between groups, as expected for treated and nontreated individuals with recent infection. The median estimated duration of infection in the seroconverter group was 8.7 months. Up to 75% of the seroconverter group were men who have sex with men; the remainder were infected through heterosexual contact.
The overall rate of drug resistance mutations in the seroconverter group was 16.8% (15 of 89 subjects). It was 27.6% ). Considering drug classes P p .076 separately, resistance to nucleoside reverse-transcriptase inhibitors (NRTIs) was recognized in 14.6% of cases, resistance to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) was recognized in 3.4%, and resistance to protease inhibitors (PIs) was recognized in 3.4%. Four patients presented with drug resistance mutations affecting 2 drug families (NRTI plus NNRTI in 2 patients and NRTI plus PI in another 2). Table 2 records the main features of the 15 members of the seroconverter group who harbored drug-resistant virus, and figure 1 records the sequence alignment of RT and protease genes.
The overall rate of drug resistance mutations in the potential transmitter group was 80%. Considering each drug family separately, the rate was 73.7% for resistance to NRTIs, 36.4% for resistance to NNRTIs, and 38.7% for resistance to PIs. The proportion of patients in this group carrying drug-resistant virus varied during the course of the study period. A significant increase was noticed in the rate of resistance to NRTIs, from 66.7% of subjects in the period 1997-1999 to 77.9% in 2002-2003 ( ). For resistance to NNRTIs, the increase was P p .017 even more pronounced, from 14.7% of subjects in the period 1997-1999 to 46.4% in June 2003 (
). This result is in P ! .001 accordance with the widespread use of NNRTIs in Spain since their approval in 1999. The overall rate of major PI resistance mutations in the potential transmitters group remained quite stable during the entire study period. Table 3 records the main drug-resistance genotypes found in subjects in the seroconverter and potential transmitter groups. The estimated ratio of drug resistance genotypes in the seroconverter group to drug resistance genotypes in the potential transmitter group was 0.23 for resistance to NRTI, 0.09 for resistance to NNRTIs, and 0.09 for resistance to PIs; the ratio was significantly lower for resistance to NNRTIs and PIs than it was for resistance to NRTIs. When considering specific ..~.. drug resistance mutations, the estimated ratios of the seroconverter group to the potential transmitter group were as follows: for mutations conferring resistance to NRTIs, the ratios were 0.18 for 41L, 0.20 for 215Y/F (including revertant forms), 0.09 for 69N, and 0.06 for 184V; for mutations conferring resistance to NNRTIs, the ratios were 0.14 for 181C and 0.04 for 103N; for mutations conferring resistance to PIs, the ratios were 0.12 for 46I/L, 0.08 for 90L, and 0.06 for 82S/A/T (figure 2).
Transmission efficiency was significantly lower for viruses with NRTI resistance mutations 69N and 184V, compared with viruses carrying 215Y or 41L. For NNRTI resistance mutations, viruses with 103N tended to be transmitted with less efficiency than viruses with 181Y. Finally, PI resistance mutation 82S/A/ T was significantly less transmissible than 46I/L. Some drug resistance mutations, such as RT L74V or K70R and protease D30N and V84I, were not recognized in the seroconverter group despite being quite prevalent in the potential transmitter group (where they were found in 10.6%, 18.8%, 3.8%, and 8.2% of members, respectively). It might be assumed that the transmission efficiency for these genotypes was low.
In an attempt to explore whether the relatively lower transmission efficiency of some drug resistance mutations could be explained, at least in part, by lower plasma viral loads in the corresponding carriers, we compared viral loads in members of the potential transmitter group who harbored specific drug resistance genotypes with those who did not. After examining multiple genotypes in different models, only the presence of the RT M184V mutation was consistently associated with lower plasma viral loads (table 4) . However, it should be noted that, in patients carrying virus with the RT 69N and 103N mutations, as well as in patients carrying virus with the protease 82A/S/T and 90M mutations, there were a significantly higher number of additional drug resistance mutations (8, 5, 6 , and 7 mutations, respectively), which, in the multivariate analysis, accounted for the apparent influence of the RT M184V mutation on viral loads. In contrast, in patients carrying virus with the RT M184V mutation, there were a median of only 4 drug resistance mutations.
DISCUSSION
In this retrospective study, nearly 17% of new HIV-1 infections in Madrid were due to drug-resistant virus. This is in agreement with the results from similar studies conducted in the United States and western Europe [6] [7] [8] . The increase in drug-resistant HIV-1 infections seen in recent years (after an apparent decrease during 2000) has been highlighted previously [16] and could be due to a growing proportion of infections derived from contacts with individuals who are not aware of their HIVpositive status, including immigrants carrying non-B subtypes [17] . This effect, however, has been counterbalanced more recently by an increasing number of patients exposed to antiretroviral therapy without complete virus suppression, as a result of either treatment interruptions or partial failure of therapy after extensive prior treatment experience. The engagement of some of these individuals in high-risk behaviors represents the source of a growing proportion of new HIV-1 infections in developed countries [18, 19] . Not surprisingly, drug-resistant virus strains often cause these new infections. Little information is known about the relative transmission efficiency of viruses with drug resistance mutations. Two major difficulties in performing this kind of study are, first, to ensure that what is measured in the seroconverter group accurately reflects the reality of disease transmission, and, second, to correctly define the population of potential transmitters of HIV-1. The closer to the time of transmission that the resistance testing is performed, the more confident one can be of the former. In our study, the median time from infection to resistance testing in the seroconverter group was 8.7 months. Although it is possible that some drug-resistant strains of the virus may have become minor populations and therefore been missed by testing, recent data have demonstrated that those who acquire drug-resistant virus tend to have persistence of that virus for prolonged periods of time after seroconversion [6, 7] .
In our study, resistance profiles in members of the seroconverter group were compared with HIV-1 genotypes found in paired case-control individuals with drug-resistant virus. Defining individuals who are potential transmitters of HIV-1 is complex. In our study, this group was represented by patients currently experiencing failure of their antiretroviral treatment and who, therefore, had a high likelihood of harboring drugresistant virus. Adjustments were performed for year of infection and transmission route. Our analysis was restricted to subjects infected through sexual contact and included both men who have sex with men and heterosexual subjects. Patients infected by parenteral mechanisms (transfusion recipients or injection drug users) were excluded from this analysis, because direct exposure to contaminated blood might reduce the chances of filtering less-transmissible drug-resistant virus. In Spain, a large proportion of persons with chronic HIV-1 infection are former injection drug users; therefore, a large proportion of heterosexuals who were included as control subjects in our study were derived from this population.
Given our decision to include only those at high risk for harboring drug-resistant virus in the potential transmitter group and to compare their resistance pattern to that found in the seroconverter group, our study did not allow us to assess the relative risk of transmission of drug-resistant virus with respect to wild-type virus. However, it allowed us to investigate whether some drug resistance genotypes could be relatively more transmissible than others.
We found lower transmission efficiency for RT 184V, 103N, and 69N mutations, as well as for protease 82A/S/T and 90M mutations, when compared with the transmission of viruses with RT 41L, 215Y/F, and 181C/I and protease 46L mutations, respectively. Several explanations may account for this observation. It is well known that some mutations compromise viral fitness much more than others [11, 13, 14] . This has been extensively proven for M184V [13] , and, not unexpectedly, we found a lower viral load in members of the potential transmitter group who carried viruses with the M184V mutation, compared with those who carried wild-type strains. Whether the lower transmission efficiency we found associated with the M184V mutation was mainly driven by overall lower viral loads in the potential transmitter group should be further investigated.
For the remaining mutations that were associated with lower transmission efficiency in this study (RT T69N and K103N and protease V82A/S/T and L90M), we could not demonstrate any association with lower viral loads (which could effect their transmission) in the potential transmitter group. However, in contrast with patients carrying viruses with the M184V mutation, members of the potential transmitter group with virus with other, less-transmissible drug resistance genotypes carried virus with many other mutations (15 mutations on average), and the cumulative effect of multiple drug resistance mutations-particularly in the protease gene-has already been shown to reduce the replicative capacity of the virus [14, 20, 21] and, hypothetically, the transmission efficiency of the virus, as well. We could not find any evidence of less transmission efficiency being associated with some drug resistance genotypes that are known to compromise viral fitness to some extent (e.g., RT L74V [22, 23] or protease D30N [14] ). The low rate of these mutations (or their absence) among both members of the potential transmitter group and/or members of the seroconverter group made it very difficult to estimate their transmission efficiency in our study.
Our study has several limitations that should be kept in mind. First, we estimated transmission efficiency rates of distinct drug-resistance genotypes after examining plasma samples obtained from both members of the potential transmitter group and newly infected persons. However, differences in HIV-1 pol sequences have been found when comparing virus present in the genital tract with virus present in blood [24] . Given that we did not examine genital samples, we cannot exclude the possibility that genotypes in semen completely correlated with those in blood. Another limitation of our study involves the sensitivity of the sequencing method we used. Population sequencing often misses virus populations present in !30% of the whole quasispecies population [15] . Therefore, some drugresistant strains of virus that were present as a minority population in members of the potential transmitter group could have been missed by our sequencing method but occasionally transmitted, making the interpretation of our results difficult.
In summary, transmission of drug-resistant HIV-1 increased in [2002] [2003] . Virus strains carrying some drug resistance mutations (e.g., strains carrying 41L or 215Y/F for resistance to NRTIs, 181C for resistance to NNRTIs, and 46L for resistance to PIs) may be more efficiently transmitted than others (e.g., strains carrying 184V for resistance to NRTIs, 103N for resistance to NNRTIs, and 82A/T/S or 90M for resistance to PIs). The impact of these strains on the natural history of and treatment outcome in newly infected individuals should be further studied.
